Peri-implantitis linked to bleeding on probing and progressive bone loss: Study

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-05-20 14:30 GMT   |   Update On 2022-05-20 14:30 GMT

Diagnosis of peri-implantitis requires the presence of Bleeding on probing (BOP) and progressive bone loss, according to new research published in the Clinical Oral Implants Research. The aim of Working Group 4 was to address topics related to biologic risks and complications associated with implant dentistry. Focused questions on (a) diagnosis of peri-implantitis, (b)...

Login or Register to read the full article

Diagnosis of peri-implantitis requires the presence of Bleeding on probing (BOP) and progressive bone loss, according to new research published in the Clinical Oral Implants Research.

The aim of Working Group 4 was to address topics related to biologic risks and complications associated with implant dentistry. Focused questions on (a) diagnosis of peri-implantitis, (b) complications associated with implants in augmented sites, (c) outcomes following treatment of peri-implantitis, and (d) implant therapy in geriatric patients and/or patients with systemic diseases were addressed.

Four systematic reviews formed the basis for discussion in Group 4. Participants developed statements and recommendations determined by group consensus based on the findings of the systematic reviews. These were then presented and accepted following further discussion and modifications as required by the plenary.

Results:

Bleeding on probing (BOP) alone is insufficient for diagnosing peri-implantitis. The positive predictive value of BOP alone for the diagnosis of peri-implantitis varies and is dependent on the prevalence of peri-implantitis within the population. For patients with implants in augmented sites, the prevalence of peri-implantitis and implant loss is low over the medium to long term. Peri-implantitis treatment protocols which include individualized supportive care, result in high survival of implants after 5 years, with about three-quarters of implants still present. Advanced age alone is not a contraindication for implant therapy. Implant placement in patients with cancer receiving high-dose antiresorptive therapy is contraindicated due to the associated high risk for complications.

Thus, Diagnosis of peri-implantitis requires the presence of Bleeding on probing (BOP) and progressive bone loss. The prevalence of peri-implantitis for implants in augmented sites is low. Peri-implantitis treatment should be followed by individualized supportive care. Implant therapy for geriatric patients is not contraindicated; however, comorbidities and autonomy should be considered.

Reference:

Group 4 ITI Consensus Report: Risks and biologic complications associated with implant dentistry by Lisa J. Heitz-Mayfield et al. published in the Clinical Oral Implants Research.

https://doi.org/10.1111/clr.13307



Tags:    
Article Source : Clinical Oral Implants Research

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News